Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of 31 Randomized Controlled Trials

Liuting Zeng1*, Tiejun Yang2†, Kailin Yang3*, Ganpeng Yu2, Jun Li2, Wang Xiang4 and Hua Chen1*

1 Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2 Department of Orthopedics, People’s Hospital of Ningxiang City, Ningxiang, Hunan, China, 3 Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, Hunan, China, 4 Department of Rheumatology, The First people’s Hospital Changde City, Changde, Hunan, China

Objective: To evaluate the randomized controlled trials (RCTs) of Curcumin and Curcuma longa Extract in the treatment of autoimmune diseases.

Methods: Databases such as Embase, Web of Science, PubMed and The Cochrane Library were searched from the database establishment to February 2022 to collect RCTs of Curcumin and Curcuma longa Extract in the treatment of autoimmune diseases. Then the literature was screened and the data were extracted. Meta-analysis was performed using RevMan 5.3 software.

Results: A total of 34 records were included, involving 31 RCTs and 10 types of autoimmune disease. Among them, ankylosing spondylitis (AS) involves one RCT, Behcet’s disease (BD) involves one RCT, Crohn’s disease involves two RCTs, multiple sclerosis (MS) involves two RCTs, oral lichen planus involves six RCTs, psoriasis involves two RCTs, rheumatoid arthritis (RA) involves five RCTs, systemic lupus erythematosus (SLE) involves two RCTs, arteritis involves one RCT, ulcerative colitis (UC) involves nine RCTs. Among them, most of the RCTs of ulcerative colitis (UC), oral lichen planus, RA showed that curcumin and curcumin extracts improved clinical or laboratory results. Crohn’s disease, MS, SLE, psoriasis included two RCTs; they all showed improvements (at least one RCT reported improvements in clinical outcomes). AS, BD and arteritis included only one RCT, and the clinical results showed improvement. However, due to the small number of RCTs and the small number of patients involved in each disease, there is still a need for more high-quality RCTs.
1 INTRODUCTION

Autoimmune diseases refer to diseases caused by the damage of the body’s own tissues caused by the immune response of the body to self-antigens (1). The main reason is that the autoimmune tolerance state is broken or the autoimmune cells are abnormally regulated under the induction of some internal and external factors such as genetic factors and environmental factors, and the immune system produces a persistent and protracted immune response to self-antigens (2, 3). Autoimmune diseases generally include systemic lupus erythematosus (SLE), Sjögren’s syndrome, multiple sclerosis (MS), rheumatoid arthritis (RA), Behcet’s disease (BD), giant cell arteritis, Takayasu arteritis, Psoriasis, ankylosing spondylitis (AS), oral lichen planus and more than 120 diseases (4, 5). Autoimmune diseases can be induced in a variety of ways, and symptoms vary depending on the disease and the organs involved. The presence of autoimmune disease often requires some blood tests to confirm (6). Treatment for autoimmune diseases depends on the type and severity of the condition. Commonly used drugs include non-steroidal anti-inflammatory drugs (NSAIDs), biologically targeted drugs (such as ustekinumab), and traditional immune-suppressing drugs (such as azathioprine and cyclosporine) (7–9). However, these drugs not only suppress the autoimmune response, but also inhibit the body’s ability to defend itself against foreign invasion, including infection-causing microorganisms and malignant tumor cells (10, 11). Therefore, the treatment of autoimmune diseases is still a difficult problem, and researchers are increasingly interested in the treatment of autoimmune diseases with natural products (12, 13).

Curcuma longa L. has been used as a traditional Chinese medicinal material mainly as turmeric for thousands of years in China (14). Curcumin is the most effective ingredient extracted from the rhizomes of ginger plants such as turmeric, curcuma, turmeric, and calamus (15). A number of in vitro and in vivo experiments showed that curcumin has various pharmacological effects such as regulating immunity, anti-oxidation, inhibiting inflammation, anti-tumor, anti-angiogenesis, anti-coagulation, and scavenging free radicals (15, 16). These studies suggest that curcumin may play a regulatory role by altering the activities of enzymes, receptors, and related transcription factors (17). Numerous randomized controlled trials (RCTs) have shown that curcumin can alleviate many human diseases, including autoimmune diseases, with the main mechanisms in regulating immunity and inhibiting inflammation. Also, curcumin is administered with few side effects, making it a potential alternative to NSAIDs and other drugs with known severe side effects (18–21). In recent years, a large number of RCTs have been published, so it is urgent to summarize and summarize the efficacy and safety of curcumin in autoimmune diseases. This study would provide future clinicians with better evidence for clinical practice by conducting a comprehensive systematic review and meta-analysis of these RCTs, as well as providing more details for future clinical trial design.

2 MATERIALS AND METHODS

2.1 Protocol

This systematic review and meta-analysis were conducted strictly in accordance with the protocol (CRD42021289248) and PRISMA-guidelines (see Supplementary Materials) (22).

2.2 Literature Search Strategy

The English databases (Medline complete, Web of Science, PubMed and Embase) and Chinese databases (Sinomed, Wanfang Database, China National Knowledge Infrastructure, VIP Database) were searched from the establishment of the database to February 2022. We also searched Cochrane Library and The ClinicalTrials.gov. The search strategy of Pubmed and Embase is shown in Table S1 as an example.

2.3 Inclusion and Exclusion Criteria

2.3.1 Participants

The patient was diagnosed with an autoimmune disease by accepted diagnostic criteria.

2.3.2 Intervention

The therapy of the experimental group was curcumin or Curcuma longa Extract preparation, regardless of dosage form, intervention dose, administration route, etc. The therapy of the control group was placebo, conventional therapy, or other curcumin-free therapy.

2.3.3 Outcomes

Outcomes are efficacy indicators, inflammatory indicators and safety indicators.
2.3.4 Design
The study design was RCTs.

2.3.5 Exclusion Criteria
(1) Literature with repeated publications, data and incomplete data. (2) Secondary literature and conference papers such as experience exchange, meta-analysis and review. (3) Animal experiments. (4) The control group therapy contains curcumin or Curcuma longa Extract. (5) abstract only.

2.4 Literature Screening and Data Extraction
First, a preliminary search was carried out in Chinese and English databases, after eliminating duplicate literature, systematic reviews, reviews and animal experiments. After further reading the titles and abstracts to eliminate obviously irrelevant literature, according to the inclusion and exclusion criteria, two researchers independently screened eligible literature and extracted data. Data extraction was performed independently by two researchers, and if there was disagreement, they were discussed with other researchers.

2.5 Quality Assessment
Quality assessment adopts the RCT risk of bias assessment tool recommended by the Cochrane Handbook (23). Quality assessment was performed independently by two researchers, and if there was disagreement, they were discussed with other researchers.

2.6 Statistical Analysis
Data analysis was performed with RevMan 5.3 software provided by the Cochrane Collaboration (24). For continuous variables, mean difference (MD) and 95% confidence interval (CI) were used as effect analysis statistics. The heterogeneity among the results of the included studies was analyzed by the $\chi^2$ test (the test level was $\alpha=0.1$), and the size of the heterogeneity was quantitatively judged by I2. If there was little or no heterogeneity among study results ($P>0.1$, $I^2 \leq 50\%$), a fixed-effect model was used. If the heterogeneity among the results of each study was large ($P \leq 0.1$, $I^2>50\%$), the source of heterogeneity was further analyzed, and the random effect model was used after excluding the influence of obvious clinical heterogeneity (25). The test level of the meta-analysis was set to $\alpha=0.05$.

3 RESULTS
3.1 Results of the Search
A total of 2991 literatures were obtained through computer database search and other methods. After deduplication, after reading the title and abstract, excluding the literature review, review, non-clinical research and obviously irrelevant literature, a total of 42 clinical studies were collected. Read the full text further to exclude articles that did not meet the inclusion criteria (26–33). Finally, a total of 34 RCT studies were included. The process and results of screening literature are shown in Figure 1.

3.2 Description of Included Trials
A total of 34 records were included, involving 31 RCT's and 10 types of autoimmune disease: AS, BD, Crohn's Disease, MS, Oral lichen planus, Psoriasis, RA, SLE, Takayasu arteritis, UC. Dolati et al. 2019 (34) and Dolati et al. 2018 (35) belong to the same RCT and thus merge into “Dolati et al. 2019 (34, 35)” Zhu and Zhu 2019 (36) and Zhu 2019 (37) belong to the same RCT and thus merge into “Zhu and Zhu 2019 (36, 37)” ; Abbasian et al. 2021 (38) and Farzaneh et al. 2022 (39) belong to the same RCT and thus merge into “Farzaneh et al. 2022 (38, 39)” . Amalraj et al. 2017 (40) and Jacob et al. 2018 (41) used two different doses of curcumin intervention (high-dose group and low-dose group), so they were divided into Amalraj et al. 2017a (low-dose group), Amalraj et al. 2017b (high-dose group), Jacob et al. 2018a (low-dose group), Jacob et al. 2018b (high-dose group). The interventions of Chandran and Goel 2012 (42) were divided into Curcumin 500 mg and Curcumin 500 mg+diclofenac sodium 50 mg, so they were also divided into Chandran et al. 2012a (Curcumin only) and Chandran et al. 2012b (Curcumin+diclofenac sodium). The details of study characteristics are presented in Table 1.

3.3 Risk of Bias of Included Studies
The summary and graph of risk of bias were shown in Figures 2, 3.

3.4 Curcumin and Curcuma longa Extract in the Treatment of Takayasu Arteritis
Only Shao et al. 2017 (43) reported the effects and safety of curcumin in the treatment of Takayasu arteritis. The study included 246 patients with Takayasu arteritis (120 in the experimental group and 126 in the control group) involving BVAS and inflammation indicators. The results showed that BVAS score after curcumin treatment was lower than that of placebo group, and TNF-α, CRP and ESR were decreased ($P<0.05$).

3.5 Curcumin and Curcuma longa Extract in the Treatment of Psoriasis
Two RCT's on the treatment of Psoriasis with Curcumin and Curcuma longa Extract, the data involved can be combined for meta-analysis, and therefore would be described according to the results of the meta-analysis.

3.5.1 PASI
Two (2) RCTs reported the PASI. The heterogeneity test showed low heterogeneity (PASI50: $I^2 = 0\%$, $P=0.47$; PASI75: $I^2 = 0\%$, $P=0.48$; PASI90: $I^2 = 0\%$, $P=0.65$), so the fixed-effects model was used. The summary results showed that addition of curcumin improved PASI50 (RR=1.57, 95%CI[1.19, 2.07], $P=0.001$), PASI75 (RR=3.01, 95%CI[1.33, 6.82], $P=0.008$) and PASI90 (RR=3.41, 95%CI[1.02, 11.36], $P=0.05$) compared to the control group (Figures 4–6).

3.5.2 Adverse Events
Two (2) RCTs reported the adverse events. The heterogeneity test showed low heterogeneity ($I^2 = 0\%$, $P=0.75$), so the fixed-effects model was used. The summary results showed that
compared with control group, the addition of curcumin did not increase the incidence of adverse events (RR=0.71, 95%CI[0.38, 1.35], P=0.29) (Figure 7).

3.6 Curcumin and Curcuma longa Extract in the Treatment of SLE
Two (2) RCTs explored the effects and safety of curcumin and curcuma longa Extract in the treatment of SLE. Khajehdehi et al. 2012 (46) included 24 patients with lupus nephritis and no adverse effects related to turmeric supplementation were observed during the trial. Singgih et al. 2017 (47) used Curcumin 60mg combined with cholecalciferol as the treatment regimen for the trial group, with a total of 40 participants. They found that the improvement of SLEDAI, the decrease of IL-6 and the decrease of TGF-β1 by Curcumin 60mg combined with cholecalciferol had no statistical difference compared with the control group (P>0.05).

3.7 Curcumin and Curcuma longa Extract in the Treatment of MS
Two (2) RCTs explored the effects and safety of curcumin and curcuma longa Extract in the treatment of MS. Dolati et al. 2019 (34, 35) utilized Nanocurcumin 80mg for patients with MS. They found that compared with placebo controls, curcumin decreased EDSS, increased Treg cells of blood peripheral mononuclear cells, and increased the expression of FoxP3, TGF-β and IL-10 mRNA in blood peripheral mononuclear cells (P<0.05) and also increased serum TGF-β and IL-10 levels (P<0.05). Petracca et al. 2021 (48) used curcumin combined with IFN-β-1a therapy to treat patients with MS; they stated that the study dropout rate was too high to draw firm conclusions. Although they found no significant difference in EDSS between the curcumin+IFN-β-1a group and placebo+IFN-β-1a group (P>0.05), they found that curcumin increased the efficacy of IFN beta-1a on the inflammatory radiological symptoms of MS (P<0.05). They also found that the addition of curcumin did not increase the probability of adverse reactions.

3.8 Curcumin and Curcuma longa Extract in the Treatment of AS
Only Ahmadi et al., 2019 explored the effects and safety of curcumin and curcuma longa Extract in the treatment of AS. They included 12 patients who received nanocurcumin and 12 who received a placebo. They found that compared with the control group, Treg cells in the nano-curcumin group increased significantly, the levels of IL-10 and TGF-β increased, and the level of IL-6 decreased (P<0.05).
| Disease | Study | Country | Sample size | Intervention | Outcomes | Age (years) | ESR (mm/h) | CRP (mg/L) | Duration |
|---------|-------|---------|-------------|--------------|----------|-------------|------------|------------|----------|
| Psoriasis | Lesion Area and Severity | **Trial group** | 12 weeks | 19.1-52.4 | 110 ± 20 | 35 ± 5 | 36 ± 4 | 4 weeks |
| SLE | **Trial group** | 12 weeks | 32 ± 14 | 35 ± 10 | 12 weeks |
| MS | **Trial group** | 12 weeks | 36.5 ± 6 | 34.3 ± 9 | 24 weeks |
| BD | **Trial group** | 12 weeks | 23-32 | 27-46 | 16 weeks |
| UC | **Trial group** | 12 weeks | 45.2 ± 15.8 | 39.7 ± 14.2 | 96 weeks |
| SLE | **Trial group** | 12 weeks | 36.7 ± 8.9 | 35.5 ± 13.8 | 8 weeks |
| MS | **Trial group** | 12 weeks | 40.4 ± 12.7 | 41.4 ± 13.9 | 4 weeks |
| BD | **Trial group** | 12 weeks | 36 ± 12 | 34 ± 7 | 8 weeks |
| UC | **Trial group** | 12 weeks | 33.96 ± 10.1 | 34.86 ± 10.27 | 8 weeks |
| UC | **Trial group** | 12 weeks | 41.43 ± 12.98 | 42.13 ± 11.78 | 12 weeks |
| SLE | **Trial group** | 12 weeks | 38.21 ± 16.37 | 36.04 ± 11.78 | 4 weeks |
| BD | **Trial group** | 12 weeks | 40.1 ± 13.2 | 40.6 ± 12.4 | 8 weeks |
| BD | **Trial group** | 12 weeks | 36.12 ± 12.7 | 34 ± 7 | 8 weeks |
| UC | **Trial group** | 12 weeks | 33.96 ± 10.1 | 34.86 ± 10.27 | 8 weeks |
| UC | **Trial group** | 12 weeks | 41.43 ± 12.98 | 42.13 ± 11.78 | 12 weeks |
| UC | **Trial group** | 12 weeks | 36.0 ± 10.5 | 37.6 ± 10.9 | 22 weeks |
| UC | **Trial group** | 12 weeks | 35.0 ± 10.5 | 37.6 ± 13.8 | 24 weeks |
| UC | **Trial group** | 12 weeks | 36.3 ± 8.9 | 32 ± 7.9 | 12 weeks |
| UC | **Trial group** | 12 weeks | 5.3 ± 2.4 | 8 weeks |
| UC | **Trial group** | 12 weeks | 21 ± 3.7 | 12 weeks |
| UC | **Trial group** | 12 weeks | 28 ± 23.7 | 12 weeks |
| UC | **Trial group** | 12 weeks | 38.75 ± 20.9 | 12 weeks |
| UC | **Trial group** | 12 weeks | 47.8 ± 8.6 | 8 weeks |
| UC | **Trial group** | 12 weeks | 47.8 ± 8.6 | 8 weeks |
| UC | **Trial group** | 12 weeks | 47.8 ± 8.6 | 8 weeks |
| UC | **Trial group** | 12 weeks | 50.68 ± 9.93 | 8 weeks |
| UC | **Trial group** | 12 weeks | 60.0 ± 8.0 | 8 weeks |
3.9 Curcumin and Curcuma longa Extract in the Treatment of BD

Only Farzaneh et al. 2022 (39) explored the effects and safety of curcumin and curcuma longa Extract in the treatment of BD. They included 17 patients in the nanocurcumin group and 15 in the placebo group. They found that BDCAF was decreased in patients treated with curcumin (P<0.05). They also found that Treg cells, the levels of IL-10 and TGF-β in the nano-curcumin group increased significantly, while IL-17 and IL-23 decreased (P<0.05). No obvious adverse events were observed in the curcumin group and the control group, suggesting that Nanocurcumin is relatively safe.
3.10 Curcumin and Curcuma longa Extract in the Treatment of UC

Nine RCTs reported the effects and safety of curcumin and curcuma longa Extract in the treatment of UC. The data involved can be combined for meta-analysis, and therefore would be described according to the results of the meta-analysis.

### 3.10.1 Clinical Activity Index

Five (5) RCTs reported clinical activity index. Due to the different scales used, SMD was used to represent the effect size. The heterogeneity test showed low heterogeneity ($I^2 = 0\%$, $P=0.54$), so the fixed-effects model was used. The summary results showed that compared with control group, the addition
of curcumin decreased the clinical activity index (SMD=-0.53, 95%CI[-0.76, -0.29], P<0.0001) (Figure 8).

3.10.2 Clinical Efficacy
Seven (7) RCTs reported clinical remission and clinical response rates, and 6 reported endoscopic remission rates. The heterogeneity test showed high heterogeneity (clinical remission: I² = 67%, P=0.005; clinical response: I² = 77%, P=0.0002; endoscopic remission: I² = 68%, P=0.009.), so the random-effects model was used. The summary results showed that compared with control group, the addition of curcumin increased the clinical remission rates (RR=2.28, 95%CI[1.43, 3.62], P=0.0005) and endoscopic remission rates (RR=1.66, 95%CI[1.07, 2.60], P=0.03) (Figures 9, 10), while the addition of curcumin did not increase the clinical remission rates (RR=1.28, 95%CI[0.86, 1.92], P=0.23) (Figure 11).

3.10.3 Inflammatory Factor
Three (3) RCTs reported ESR and CRP. For ESR, the heterogeneity test showed low heterogeneity (I² = 5%, P=0.35), so the fixed-effects model was used. The summary results showed that compared with control group, the addition of curcumin decreased the ESR (SMD=-0.61, 95%CI[-0.95, -0.28], P=0.0003) (Figure 12).

For CRP, the heterogeneity test showed high heterogeneity (I² = 91%, P<0.0001), so the random-effects model was used. The summary results showed that compared with control group, the addition of curcumin decreased the CRP (SMD=-1.25, 95%CI[-2.36, -0.14], P=0.03) (Figure 13).

3.10.4 Adverse Events
Five (5) RCTs reported the adverse events. The heterogeneity test showed low heterogeneity (I² = 0%, P=0.62), so the fixed-effects model was used. The summary results showed that compared with control group, the addition of curcumin did not increase the incidence of adverse events (RR=1.02, 95%CI[0.51, 2.03], P=0.95) (Figure 14).

3.11 Curcumin and Curcuma longa Extract in the Treatment of Crohn’s Disease
Two (2) RCTs explored the effects and safety of curcumin and curcuma longa Extract in the treatment of Crohn’s Disease. Bommelaer et al. 2020 (59) found that Curcumin was no more
effective than placebo in preventing Crohn’s disease relapse and probably did not improve patients’ quality of life. Thiopurine was discontinued due to nausea and abdominal pain in 2 patients each in the curcumin and placebo groups. In addition, adverse events were reported in 2 patients in the placebo group (1 pregnancy and 1 abscess) and 5 patients in the curcumin group (2 abdominal pain, 1 vomiting, 1 migraine, and 1 cervical squamous cell carcinoma); and these are not considered to be related to the addition of curcumin. However, (60) found that with the addition of curcumin, clinical remission and Endoscopic remission improved, and no serious adverse events were observed. Only one patient...
showed mild appetite loss, which did not affect the completion of the clinical trial.

3.12 Curcumin and Curcuma longa Extract in the Treatment of RA

Five RCTs reported on the treatment of RA with Curcumin and Curcuma longa Extract, the data involved can be combined for meta-analysis, and therefore would be described according to the results of the meta-analysis.

3.12.1 DAS28

Four (4) RCTs reported the DAS28. The heterogeneity test showed high heterogeneity (I² = 85%, P<0.00001), so the random-effects model was used. The summary results showed that compared with control group, the addition of curcumin decreased the DAS28 (WMD=-1.10, 95%CI[-1.67, -0.53], P=0.0002) (Figure 15).

3.12.2 Inflammatory Factor

Five (5) RCTs reported the ESR. The heterogeneity test showed high heterogeneity (I² = 91%, P<0.00001), so the random-effects model was used. The summary results showed that compared with control group, the addition of curcumin decreased the ESR (SMD=-3.09, 95%CI[-4.60, -1.58], P<0.0001) (Figure 16). Four (4) RCTs reported the CRP. The heterogeneity test showed high heterogeneity (I² = 91%, P<0.00001), so the random-effects model was used. The summary results showed that compared with control group, the addition of curcumin decreased the CRP (SMD=-2.15, 95%CI[-3.32, -0.97], P=0.0003) (Figure 17).

3.12.3 Adverse Events

Three (3) RCTs reported the adverse events. The heterogeneity test showed low heterogeneity (I² = 0%, P=0.78), so the fixed-effects model was used. The summary results showed that compared with control group, the addition of curcumin did not increase the incidence of adverse events (RR=0.31, 95%CI [0.06, 1.64], P=0.17) (Figure 18).

3.13 Curcumin and Curcuma longa Extract in the Treatment of Oral lichen planus

Six RCTs reported Curcumin and Curcuma longa Extract in the Treatment of Oral lichen planus. (64, 67) found that Curcumin may decrease Modified oral mucositis index (P<0.05). However, (68) found no significant difference in efficacy between Curcumin and Prednisolone. Since their indicators could not
be combined, Meta-analysis was not conducted. (63–65) found no significant adverse events. (65, 66) reported Thongprasom score, which could be combined. The heterogeneity test showed low heterogeneity (I² = 0%, P=0.78), so the fixed-effects model was used. The summary results showed that compared with control group, the addition of curcumin did not decrease Thongprasom score (WMD=-0.35, 95%CI[-0.85, 0.15], P=0.17) (Figure 19).
4 DISCUSSION

4.1 Mechanisms of Curcumin Regulation of Immune Cells in Autoimmune Diseases

Autoimmune diseases are a series of diseases caused by the immune system’s immune response to self-antigens, leading to self-tissue damage or dysfunction (69, 70). Many autoimmune diseases are characterized by the production of autoantibodies that bind to the host’s own proteins or form immune complexes that deposit in tissues (71, 72). Any organ may become a target organ of autoimmunity, including skin, joints, kidneys, blood vessels, etc. (73). Inflammatory effects caused by autoantibodies are mediated by binding to Fc receptors on leukocytes and are an important cause of downstream tissue damage. Meanwhile, autoantibodies can also directly mediate tissue damage in disease through complement activation (74). During the developmental stage of the disease, genetic and environmental factors may in turn interact to promote the development of autoimmunity, ultimately leading to tissue inflammation and damage (75).

In autoimmune diseases, the balance between the body’s recognition of foreign pathogens and the immune system’s attack on self-antigens is disrupted, resulting in abnormal immune tolerance. During the breakdown of immune tolerance, initiating tissues provide a microenvironment that influences immune cell differentiation leading to the activation of adaptive immunity. Type 1 interferons produced by innate immune cells play a central role in systemic autoimmunity and activate B and T cells, while B cell-derived autoantibodies stimulate dendritic cells, which in turn produce type 1 interferons. Therefore, the adaptive immune response pathway and the innate immune response pathway play important roles in the pathogenesis of systemic autoimmunity (76–78). Studies have shown that systemic autoimmune diseases (such as RA, SLE, etc.) share common genetic risk loci, and the pathogenic mechanisms may be similar (79–84). Dysregulation of basic innate immune strategies, such as the complement pathway, IFN synthesis and response to IFN, and neuromodulatory mechanisms of immune responses, contribute to autoimmunity and tissue damage in SLE (85–88).

Adaptive immune cells in the adaptive immune system also play an important role. With the activation of dendritic cells, more interferon is produced in the autoimmune response, which promotes and maintains the self-reaction, keeps the activated T cells and B cells in a vicious circle, and produces autoantibodies. Various cytokines activate Naive T cells to promote their (Naive T cells) differentiation into helper T cells (Th cells) and Regulatory T (Treg) through different transcription factors. These Th cells and
Treg further secrete different cytokines, which in turn recruit different immune cells and coordinate different immune effector mechanisms (89, 90). There are also interactions between different subgroups, forming complex regulation and action mechanisms (91).

Curcumin has been shown to be a potent immunomodulator, which can modulate the activity of T cells, B cells, macrophages, neutrophils, NK cells, and dendritic cells (92, 93). The diverse pharmacological activities of curcumin stem from its ability to interact with different biological targets and signaling pathways (94). The immunomodulatory activity of curcumin may involve the direct targeting (activation) of TLRs (such as TLR4: the receptor for LPS) through pathogen-associated molecular patterns (PAMPs) (95). It may also be attributed to the regulation of various transcription factors, such as nuclear factor (NF-κB), activator protein 1 (AP-1), signal transducer and activator of transcription (STAT) and their downstream signaling pathways (96–100).

In the regulation of immune cells of the innate immune system: curcumin inhibits the maturation of DCs by inhibiting IDO expression through a cyclooxygenase (COX-2)/prostaglandin E2 (PG-E2)-dependent pathway (101, 102). Several curcumin treatments can reduce neutrophil recruitment to inflamed tissues through direct effects on neutrophil chemotaxis and chemotaxis (103, 104). Curcumin can reduce the production of antibodies (IgG2a, IgE and IgG1, especially IgG1) in rat splenocytes in response to LPS (105, 106). The immunomodulatory effects of curcumin on CD8+ and CD4+ T cell subsets such as curcumin can inhibit the production of Th1 cytokine profile in CD4+ T cells by inhibiting the production of IL-12 in macrophages (107). From a morphological point of view, intestinal dendritic cells (DC) treated with curcumin caused intestinal T cells to become unresponsive. Furthermore, the antigen-presenting properties of curcumin-treated DCs are blocked, resulting in reduced induction of the adaptive immune system (108). DCs treated with curcumin stimulated the differentiation of intestinal Tregs, which prevented disease progression in an animal model of colitis (109). Other studies have shown that curcumin pretreatment of DCs inhibits LPS-stimulated NF-kB p65 translocation and MAPK phosphorylation, thereby reducing inflammation (99). Curcumin also reduced proinflammatory cytokine upregulation, primarily IL-12, and hindered Th1-type responses in DCs. In addition, curcumin has been shown to reduce the expression of ICAM-1 (intercellular adhesion molecule-1) and CD11c, proteins involved in cell adhesion and T cell stimulation, possibly through an AP-1-dependent pathway.

In modulating B-cell immunity: In vitro studies have also shown that curcumin reduces serum levels of BAFF following total IgG, Toll-like receptor (TLR) 4 stimulation. It also reduced B cell activation in MRL/lpr mice and reduced lupus nephritis in MRL/lpr mice. This may represent a holistic treatment strategy in the management of SLE (110).

In regulating T cell immunity: Low-dose curcumin treatment (0.1 and 1 µg/ml) was also shown to reduce Th17 cells, IL-17A levels, and increase Treg and TGF-β1 concentrations on CD4+ T cells in SLE patients compared with normal controls (111). Various studies have reported that curcumin can precisely alter Th17/Treg balance on CD4+ T cells and alleviate organ damage in SLE subjects (111). Kalim et al. also found reduction in Th17 and improvement in Treg cells following administration of 200 mg kg day-1 curcumin in a mouse model of SLE (112). Furthermore, curcumin intervention in T cells obtained from a mouse model of psoriasis showed that 10 µM curcumin concentration significantly blocked the secretion of IL-17, IL-22, IFN-γ, IL-2, IL-8 and TNF-α (113). Xie et al. (114) found a reduction in the severity of EAE in rats treated with curcumin. Curcumin attenuated the severity of experimental allergic encephalomyelitis (EAE) due to inhibition of Th17 cell differentiation and growth by downregulating IL-6, IL-21, RORαt signaling and STAT3 phosphorylation. Along these lines, Liu et al. found that the viability of CD4+ T cells in vitro was considerably inhibited by curcumin treatment, and furthermore, curcumin induced significant apoptosis of Th1, Th17 and Treg cells (115).

4.2 Curcumin for Takayasu Arteritis

Only one RCT reported the effects and safety of curcumin in the treatment of Takayasu arteritis. They found that curcumin may improve BVAS and inflammation indicators. Therefore, TNF-α was considered to be significantly associated with a decrease in BVAS score ($\gamma^2 = 0.81$, P = 0.016), ESR ($\gamma^2 = 0.76$, P = 0.037), and plasma CRP level ($\gamma^2 = 0.79$, P = 0.041). The findings suggest that curcumin may significantly improve the therapeutic effect through its anti-TNF-α effect (43). However, more reports are needed to further verify the therapeutic effect and safety of curcumin on Takayasu arteritis.

4.3 Curcumin for Psoriasis

This study included 2 relevant RCTs and found that curcumin improved PASI in patients with psoriasis without increasing side effects compared with controls. Psoriasis is a multifactorial mediated chronic inflammatory hereditary skin disease characterized by inflammatory erythema overlying multiple layers of silvery-white mica-like scales with localized or widespread systemic distribution (116). The incidence of psoriasis vulgaris in the general population is relatively high, and the incidence in European and American countries is about 2.1%, while that in China is about 0.123%, which can seriously affect the interpersonal communication and daily life of patients (117). At present, it is generally believed that psoriasis is caused by immune imbalance caused by external stimuli such as infection, trauma, mental stress and other factors under the influence of the patient’s genetic susceptibility (118). The role of immunity in the pathogenesis of psoriasis has been widely accepted, and psoriasis genome-wide scans have also shown that most susceptibility genes are associated with immunity (119, 120). The immunological mechanism of psoriasis is complex. The main participants are keratinocytes and a variety of immune cells, including dendritic cells, macrophages, neutrophils and T cells in innate and adaptive immunity (121, 122). The relationship between innate immunity and adaptive immune system of psoriasis is realized by cytokines. The
representative inflammatory factors include TNF-α, IFN-γ, IL-17 A and IL-1, and the inhibitory inflammatory factors (regulatory inflammatory factors) include IL-4, IL-10 and TGF-β. Activated cytokines bind to corresponding receptors as specific ligands, and coordinately mediate the pathological changes of psoriasis. Both the adaptive immune system and the innate immune system can mediate the production of inflammatory mediators, and the latter play an important role in the induction and maintenance of dermal and epidermal psoriasis pathological changes. Different topical and systemic treatment options are currently available for the treatment of psoriasis, but they have suboptimal clinical outcomes and risk side effects. Multiple current studies have reported that curcumin can reduce oxidative stress in psoriatic lesions. In addition, the therapeutic efficacy of curcumin may also be related to its ability to inhibit phosphorylase kinase. Curcumin may inhibit the proliferation of psoriasis-like cells by down-regulating pro-inflammatory cell (HaCaT cell) factors such as IL-17, TNF-α, INF-γ and IL-6. Furthermore, curcumin significantly enhanced skin barrier function by upregulating involucrin (iNV) and filaggrin (FLG). Curcumin can inhibit the pro-proliferation effect of VEGF on HaCaT cells and promote the apoptosis of HaCaT cells. In vivo studies have shown that curcumin has no observed side effects in the treatment of psoriasis patients, and the U.S. Food and Drug Administration (FDA) has defined curcumin as “generally regarded as safe” (GRAS). In summary, curcumin has great potential as a treatment for psoriasis. However, more RCTs are needed to further verify the therapeutic effect and safety of curcumin on Psoriasis.

### 4.4 Curcumin for SLE

Only Two (2) RCTs explored the effects and safety of curcumin and curcuma longa Extract in the treatment of SLE. They found no increase in side effects with the addition of curcumin, and found that curcumin may improve SLEDAI and reduce IL-6 and TGF-β1. However, since the data could not be combined for meta-analysis, they need to be interpreted with caution. SLE is the most diverse autoimmune disease, which can affect any organ of the body, can have a wide range of clinical and immunological manifestations, and its incidence is increasing year by year. SLE is characterized by the presence of multiple autoantibodies in serum. Autoantibodies closely related to SLE mainly include antinuclear antibodies, anti-Sm antibodies, anti-double-stranded DNA antibodies, and anti-SSA antibodies. High titters of double-stranded DNA are associated with SLE glomerular deposition and nephritis activity, and antiphospholipid antibodies are associated with SLE prone to coagulation. Treatment options for SLE depend on the organ involved. Patients with mild symptoms can be treated with low-dose corticosteroids and are usually controlled, but moderate and severe disease may require higher doses of corticosteroids or other immunosuppressants. Pharmacological studies of curcumin on SLE showed that SLE is characterized by the activation of the complement system, and curcumin can inhibit the complement cascade. Curcumin can prevent oxidative stress of oxidatively modified proteins by binding to proteins, and can also inhibit the activation of B cells to effectively treat SLE. Low doses of curcumin can also specifically regulate Th17/Treg balance in CD4 + T cell cultures from SLE. Curcumin reduced proteinuria and serum levels of IgG1, IgG2a and anti-dsDNA IgG antibodies in female NZB/W F1 mice. In summary, curcumin may enhance regulatory responses involving T reg cells by inhibiting antibody-antigen interactions, reducing autoantigen-autoantibody deposition in tissues and various microvascular beds, and inhibiting antibody production. However, more RCTs are needed to further verify the therapeutic effect and safety of curcumin on SLE.

### 4.5 Curcumin for MS

Only Two (2) RCTs explored the effects and safety of curcumin and curcuma longa Extract in the treatment of MS. They both found that curcumin could reduce inflammatory factors, however, their findings were different on the improvement of EDSS. However, since the data could not be combined for meta-analysis, they need to be interpreted with caution. MS is an inflammatory demyelinating disease of the central nervous system that affects millions of people around the world, and approximately 30% of MS patients develop clinical paralysis. Destruction of myelinating oligodendrocytes is a pathological feature of MS, and axonal deformation leads to irreversible long-term disability. The activation of immune cells, the secretion of inflammatory cytokines and the differentiation of Th1 cells are the key processes in the pathogenesis of MS. EAE is an autoimmune disease of the central nervous system that has been used as a model to study the pathogenesis of MS and to test the efficacy of treatments for MS. Yang et al. observed the protective effect of curcumin in the treatment of EAE in SJL/J rats, and found that 50-100 mg of curcumin administered by gavage every other day could alleviate the symptoms of EAE in SJL/J rats. In addition, curcumin can inhibit neural antigen-induced T cell proliferation, Th1 differentiation, and TNFγ production. Yang et al. found that curcumin can significantly improve the clinical symptoms of EAE rats, inhibit the infiltration of inflammatory cells, and promote the recovery of rats, thereby treating MS. In EAE-induced rats, curcumin treatment was found to significantly reduce the number of inflammatory cells infiltrating the spinal cord. Curcumin treatment was also associated with upregulation of IL-10 levels and increased percentage of CD4 + CD25 + Foxp3 + Treg cells in the CNS and lymphoid organs in EAE-induced C57BL/6 mice. Furthermore, curcumin ameliorated EAE in SJL/J mice by inhibiting IL-12 signaling through the JAK-STAT pathway, resulting in reduced Th1 differentiation. In vivo treatment with curcumin has been shown to increase the expression of PPARγ in the central nervous system and lymphoid organs of EAE mice, suggesting that it is involved in the regulation of Th1/Th17 responses in EAE. Curcumin may inhibit IL-17 mRNA expression and T cell INF-γ levels in MS patients. Curcumin may inhibit the proliferation of TEM cells and the production of pro-inflammatory cytokines by inhibiting the hKv1.3 channel, which contributes to the curcumin’s efficacy in the treatment of autoimmune diseases. These basic experimental results all suggest that curcumin may be used to treat MS, therefore, more RCTs are still needed to further verify the therapeutic effect and safety of curcumin on MS.
4.6 Curcumin for AS
Only (49) explored the effects and safety of curcumin and curcuma longa Extract in the treatment of AS. They found that Treg cells increased significantly, the levels of IL-10 and TGF-β increased, and the level of IL-6 decreased after curcumin intervention. AS is a disease characterized by inflammation of the sacroiliac joints and spinal attachments as the main symptom, mainly affecting the axial skeleton, sacroiliac joints, and peripheral joints, and can cause structural changes and dysfunction (153, 154). The main clinical features of AS are intermittent low back pain, discomfort and stiffness in other parts of the body (155), which eventually progresses to spinal immobility and rigidity (156). Recent studies have shown that AS is also a T lymphocyte-mediated disease, which is supported by changes in the frequency of CD4 + T cells in the peripheral blood of patients with AS, including an increase in Th17 frequency with Th2 and a decrease in CD4 + CD25 + Treg (157–159). The results of most studies suggest that the Treg/Th17 ratio is reduced in the PB of AS patients, and speculate that altered immunophenotypes may play a role in the pathogenesis of these diseases, thus modulating the balance between Treg and Th17 may reduce disease activity (160, 161). Recent studies have found that curcumin may enhance Treg differentiation by increasing FoxP3 expression (111, 162), which is consistent with the RCT findings of Ahmadi et al., 2019. However, more RCTs are still needed to further verify the therapeutic effect and safety of curcumin on MS.

4.7 Curcumin for BD
Only (39) explored the effects and safety of curcumin and curcuma longa Extract in the treatment of BD. They found that BDCAF was decreased in patients treated with curcumin. They also found that Treg cells, the levels of IL-10 and TGF-β in the nanocurcumin group increased significantly, while IL-17 and IL-23 decreased. No obvious adverse events were observed in the curcumin group and the control group. BD is a systemic inflammatory disease with oral and vulvar ulcers and uveitis as the main clinical manifestations (163). Pathological manifestations are vasculitis involving various vascular diameters, with a tendency to thrombosis (164). The pathogenesis of BD is unclear. In addition to environmental and genetic factors, abnormal T cell immune responses are also involved in the pathogenesis, involving innate immune γδ T cells, identification of characteristic antigens, antigen presentation, and adaptive immunity represented by CD4+ and CD8+ T cells. (165, 166). The imbalance of T cell homeostasis is mainly manifested by the activation, proliferation and Treg cell damage of Th1 and Th17 helper T cells (167). The above-mentioned abnormal immune response induces and maintains the pro-inflammatory environment of BD (168). Previous studies have described that curcumin enhances the mucosal healing process of oral ulcers in humans and animals (169–171). Mohammad et al. found that the mRNA expression of IL-1β and the protein production of IL-6 and TNFα were significantly down-regulated in M1 macrophages from BD patients after curcumin (30 µg/ml) intervention (172). Curcumin also reduced macrophage polarization and production of proinflammatory cytokines IL-1β and TNFα in the human macrophage cell line M1 (173–175), which is consistent with the RCT report of (39). However, more RCTs are still needed to further verify the therapeutic effect and safety of curcumin on BD.

4.8 Curcumin for UC and Crohn’s Disease
Nine RCTs reported the effects and safety of curcumin and curcuma longa Extract in the treatment of UC. Two (2) RCTs explored the effects and safety of curcumin and curcuma longa Extract in the treatment of Crohn’s Disease. Curcumin may improve the clinical activity index, clinical response and endoscopic response, and decrease the ESR and CRP for patients with UC. (59) found that Curcumin was no more effective than placebo in preventing Crohn’s disease relapse and probably did not improve patients’ quality of life. (60) found that with the addition of curcumin, clinical remission and Endoscopic remission improved. Meanwhile, the addition of curcumin may not increase the incidence of adverse events. However, more RCTs are still needed to further verify the therapeutic effect and safety of curcumin on UC and Crohn’s Disease.

Inflammatory bowel disease (IBD) is currently considered to be an autoimmune disease, mainly including ulcerative colitis (UC) and Crohn’s disease, which are histopathologically manifested as intestinal mucosal inflammation (176, 177). IBD is an autoimmune disease involving autoantibodies and autoreactive CD4+ T lymphocytes. CD4+ T cells are essential for regulating immune homeostasis in the gut, and innate immune abnormalities will cause CD4+ T cells (Th1, Th2, Th17) to produce a large number of pro-inflammatory factors, making the immune response beyond the range of Treg regulation, thereby causing IBD (178, 179). Although the pathogenesis of UC and Crohn’s disease is characterized by an immune response to gut (bacterial) antigens, they differ in the type of inflammatory response. The pathogenesis of Crohn’s disease is mainly related to the inflammatory response dominated by cytokines IL-1, IL-6, IL-8, TNFα and IFN-γ secreted by Th1 and Th17 cells (180). UC is related to the inflammatory response dominated by cytokines such as IL-4, IL-5, IL-9 and IL-13 secreted by Th2 cells (181). Therefore, it is possible to try to regulate the CD4+ T cell population and related cytokines and signaling pathways as one of the means of IBD treatment (182, 183). Zhang et al. (148) found that curcumin decreased the expression of Th1 cytokines and up-regulated the expression of Th2 cytokines in the colonic mucosa. Lee et al. (179) also found that curcumin could alleviate ovalbumin (OVA)-induced food allergy by regulating the balance between Th1/Th2. This indicates that curcumin plays an anti-inflammatory role by changing the immune balance between Th1-Th2. It is possible to try to regulate the CD4+ T cell population and related cytokines and signaling pathways as one of the means of IBD treatment (182, 183). Zhang et al. (148) found that curcumin decreased the expression of Th1 cytokines and up-regulated the expression of Th2 cytokines in the colonic mucosa. Lee et al. (179) also found that curcumin could alleviate ovalbumin (OVA)-induced food allergy by regulating the balance between Th1/Th2. This indicates that curcumin plays an anti-inflammatory role by changing the immune balance between Th1-Th2. It is possible to try to regulate the CD4+ T cell population and related cytokines and signaling pathways as one of the means of IBD treatment (182, 183). Zhang et al. (148) found that curcumin decreased the expression of Th1 cytokines and up-regulated the expression of Th2 cytokines in the colonic mucosa. Lee et al. (179) also found that curcumin could alleviate ovalbumin (OVA)-induced food allergy by regulating the balance between Th1/Th2. This indicates that curcumin plays an anti-inflammatory role by changing the immune balance between Th1-Th2. It is possible to try to regulate the CD4+ T cell population and related cytokines and signaling pathways as one of the means of IBD treatment (182, 183). Zhang et al. (148) found that curcumin decreased the expression of Th1 cytokines and up-regulated the expression of Th2 cytokines in the colonic mucosa. Lee et al. (179) also found that curcumin could alleviate ovalbumin (OVA)-induced food allergy by regulating the balance between Th1/Th2. This indicates that curcumin plays an anti-inflammatory role by changing the immune balance between Th1-Th2. It is possible to try to regulate the CD4+ T cell population and related cytokines and signaling pathways as one of the means of IBD treatment (182, 183).
STAT3 pathway (186). Yang et al. (187) showed that curcumin can inhibit the expression of cyclinD1 and CDK4 with cell proliferation effect by inhibiting the STAT-3 signaling pathway, showing anti-inflammatory effect in IBD. Guo et al. (188) found that flavon may increase the level of peroxisome proliferator-activated receptor-\( \gamma \) (PPAR-\( \gamma \)), inhibit the STAT3 signaling pathway, reduce the release of COX-2, and reduce the infiltration of neutrophils.

### 4.9 Curcumin for RA

Five RCTs reported the effects and safety of curcumin and curcuma longa Extract in the treatment of RA. They found that curcumin may decrease DAS28, ESR and CRP. Meanwhile, the addition of curcumin may not increase the incidence of adverse events. However, more RCTs are still needed to further verify the therapeutic effect and safety of curcumin on RA.

RA is a systemic autoimmune disease characterized by chronic destructive joint disease (189, 190), and 0.5% to 1% of the world’s population is affected by RA (191). RA is characterized by synovitis and pannus production, and activated macrophages and dendritic cells are important sources of key inflammatory cytokines, including TNF-\( \alpha \) and IL-1, as well as promoting inflammatory cells. Accumulated and synthesized cytokines, such as chemokines, matrix metalloproteinases (MMPs), COX-2 and other inflammatory mediators (192, 193). CD4+ Th cells play a key role in the occurrence of immune responses, B cells contribute to the progression of inflammation, and RA occurs by activating T cells (194). The main drugs for the treatment of RA include NSAIDs, disease-modifying anti-rheumatic drugs (DMARDs), and biological agents (190, 195), but these drugs have serious side effects. Curcumin was found to have anti-rheumatic activity in humans (196). Curcumin can inhibit the occurrence and development of RA mainly by inhibiting inflammatory cytokines and MMPs and blocking signaling pathways, including mitogen-activated protein kinase, activator protein-1 and nuclear factor-\( \kappa B \) receptor activator ligand, etc. (197). Shang (198) found that curcumin can effectively inhibit angiogenesis by inhibiting the expression of hypoxia-inducible factor 1-\( \alpha \), thereby protecting the synovium of joints. In addition, curcumin protects chondrocytes by inhibiting the activation of caspase-3 by preventing the integration of IL-1\( \beta \) (199). Curcumin can reduce the gene expression of adhesion molecules, \( \beta 3 \) and \( \beta 7 \) integrins, thereby reducing joint inflammation in RA (200).

### 4.10 Curcumin for Oral Lichen Planus

Six RCTs reported Curcumin and Curcuma longa Extract in the Treatment of Oral lichen planus. (64), (67) found that curcumin may decrease Modified oral mucositis index. However, (68) found no significant difference in efficacy between Curcumin and Prednisolone. Since their indicators could not be combined, Meta-analysis was not conducted, and meta-analysis showed that curcumin may not reduce Thongprasom score. Therefore, more RCTs are still needed to further verify or modify the therapeutic effect and safety of curcumin on Oral lichen planus. Oral lichen planus is a chronic inflammatory disease of the oral mucosa of unknown etiology (201). At present, its pathogenesis is often related to mental factors, immune factors, infectious factors, endocrine factors, lack of trace elements, microcirculation disorders, and some systemic diseases (202, 203). The basis of Oral lichen planus may be T cell-mediated responses to unknown triggers (204, 205). Observational studies have also shown that patients with Oral lichen planus are more prone to an antioxidant-oxidative stress imbalance (206, 207). Treatment for Oral lichen planus is aimed at managing symptoms. Topical or systemic application of glucocorticoids and immunosuppressants is the main clinical treatment for Oral lichen planus. Although it can obtain a relatively reliable curative effect, its long application period and many adverse reactions lead to poor patient compliance, which is the main problem that plagues clinical diagnosis and treatment (202, 208). Meanwhile, there is still a lack of safer and more effective treatment options for some patients with intractable damage or those with complex systemic history. Curcumin, an active phytochemical in turmeric, is a strongly hydrophobic compound with poor bioavailability, which poses challenges for oral ingestion (209). On the other hand, curcumin was not shown to be toxic at doses of 8 g per day, making it a potentially attractive alternative to drugs currently used to treat various diseases (210).

### 4.11 Implications for the Future

Current pharmacological studies have shown that Curcumin and Curcuma longa Extract seems to reverse some clinical symptoms of many autoimmune diseases by regulating immune inflammatory biological modules, such as inflammatory factors (such as IL-1, IL-17, IL-6, IL-12, TNF-\( \alpha \) and IFN-\( \gamma \)) -mediated inflammatory signaling pathways and immune inflammatory cell activation, differentiation and immune function regulation. Curcumin and Curcuma longa Extract is an effective natural compound with a variety of therapeutic pharmacological properties and almost no side effects. Recent studies have shown that curcumin can synergistically enhance the synergistic effect of glucocorticoids and alleviate glucocorticoid-induced osteoporosis (211, 212). Therefore, the future design of RCTs may consider combining Curcumin and Curcuma longa Extract with existing conventional drug therapies such as glucocorticoids. It may be a potential side effect of reducing glucocorticoid dose and preventing glucocorticoid use to autoimmune diseases. Future RCTs should accurately determine the appropriate dose, dosage regimen, treatment duration, and further clarify the mechanism of action related to systemic autoimmune diseases. In terms of treatment and preparation, an important issue in the treatment of autoimmune diseases by oral Curcumin and Curcuma longa Extract is to improve its bioavailability (213). Although a large number of studies have been conducted on curcumin preparations to improve bioavailability, it still needs to be further improved.

### 5 CONCLUSION

This systematic review and meta-analysis evaluated the efficacy and safety of Curcumin and Curcuma longa Extract in
autoimmune diseases, such as AS, BD, Crohn’s Disease, MS, Oral lichen planus, Psoriasis, RA, SLE, Takayasu arteritis, UC. Because of its good clinical safety, the dose of curcumin in the treatment of autoimmune diseases is mainly between 80 mg and 6000 mg. The results of Meta-analysis showed that Curcumin and Curcuma longa Extract had good clinical efficacy in the treatment of Psoriasis, UC and RA, so Curcumin and Curcuma longa Extract could be used in the treatment of the above diseases in the future. The results of Meta-analysis showed that Curcumin and Curcuma longa Extract did not show efficacy in the treatment of oral lichen planus, while Takayasu arteritis, SLE, MS, AS, BD and CD did not report sufficient clinical data for meta-analysis; hence, more RCTs are still needed in the future. Curcumin and Curcuma longa Extract may regulate inflammatory cells (such as Treg) and inflammatory factors (such as CRP, ESR, TNF-α, TGF-β1, IL-6 level), which may be its mechanism for treating autoimmune diseases. However, due to the low quality and small number of RCTs in most autoimmune diseases, the conclusions need to be carefully interpreted. At present, large-sample, multi-center clinical trials are still needed for revision or validation.

REFERENCES
1. Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, et al. Vitamin D and Marine Omega 3 Fatty Acid Supplementation and Incident Autoimmune Disease: VITAL Randomized Controlled Trial. BMJ (2022) 376:e66452. doi: 10.1136/bmj-2021-066452
2. Moulton VR. Sex Hormones in Acquired Immunity and Autoimmune Disease. Front Immunol (2018) 9:2279. doi: 10.3389/fimmu.2018.02279
3. Wang C, Liao Q, Hu Y, Zhong D. T Lymphocyte Subset Imbalances in Patients Contribute to Ankylosing Spondylitis. Exp Ther Med (2015) 9:250–256. doi: 10.3892/etm.2014.2046
4. Rose NR. Prediction and Prevention of Autoimmune Disease in the 21st Century: A Review and Preview. Am J Epidemiol (2016) 183(5):403–6. doi: 10.1093/aje/kkv292
5. Zhang Y, Liu J, Wang C, Liu J, Lu W. Toll-Like Receptors Gene Polymorphisms in Autoimmune Disease. Front Immunol (2021) 12:672346. doi: 10.3389/fimmu.2021.672346
6. Kapsogeorgou EK, Tzioufas AG. Autoantibodies in Autoimmune Diseases: Clinical and Critical Evaluation. Isr Med Assoc J (2016) 18(9):519–24.
7. Yasunaga M. Antibody Therapeutics and Immunoregulation in Cancer and Autoimmune Disease. Semin Cancer Biol (2020) 64:1–12. doi: 10.1016/j.semcancer.2019.06.001
8. Zarrin AA, Bao K, Lupardus P, Vucic D. Kinase Inhibition in Autoimmunity and Inflammation. Nat Rev Drug Discovery (2021) 20(1):59–63. doi: 10.1038/s41573-020-0082-8
9. Murdaca G, Tomacci A, Negrii S, Greco M, Borro M, Puppo F, et al. Emerging Role of Vitamin D in Autoimmune Diseases: An Update on Evidence and Therapeutic Implications. Autoimmun Rev (2019) 18(9):102350. doi: 10.1016/j.autrev.2019.102350
10. Mok CC. Therapeutic Monitoring of the Immuno-Modulating Drugs in Systemic Lupus Erythematosus. Expert Rev Clin Immunol (2017) 13(1):35–41. doi: 10.1080/17445699.2016.1212659
11. Kaul A, Gordon C, Crow MK, Tsouma Z, Urowsky MB, van Vollenhoven R, et al. Systemic Lupus Erythematosus. Nat Rev Dis Primers (2016) 2:16039. doi: 10.1038/nrdp.2016.39
12. Zhang Q, Liu J, Zhang M, Wei S, Li R, Gao Y, et al. Apoptosis Induction of Fibroblast-Like Synoviocytes Is an Important Molecular-Mechanism in Treating Rheumatoid Arthritis. Biomolecules (2019) 9(12):795. doi: 10.3390/biom9120795
13. Paolillo-Pacholato AB, Marchi LF, de Andrade MF, Kabya LM, Donadi EA, Lucisano-Valim YM. Fcy and Complement Receptors and Complement Proteins in Neutrophil Activation in Rheumatoid Arthritis: Contribution to Pathogenesis and Progression and Modulation by Natural Products. Evid Based Complement Alternat Med (2015) 2015:429878. doi: 10.1155/2015/429878
14. Kocadam B, Şahinler N, Curcumin, an Active Component of Turmeric (Curcuma Longa), and Its Effects on Health. Crit Rev Food Sci Nutr (2017) 57(13):2889–95. doi: 10.1080/10408398.2015.1077195
15. Soleimani V, Sahhekar A, Hosseinzadeh H. Turmeric (Curcuma Longa) and its Major Constituent (Curcumin) as Nontoxic and Safe Substances: Review. Phytother Res (2018) 32(6):985–95. doi: 10.1002/ptr.6054
16. Sharifi-Rad J, Rayoss VE, Rizk AA, Sadaka C, Zghib R, Zam W, et al. Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Front Pharmacol (2020) 11:1021. doi: 10.3389/fphar.2020.01021
17. Kotha RR, Luthria DL. Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects. Molecules (2019) 24(16):2930. doi: 10.3390/molecules24162930
18. Ahmad RS, Hussain MB, Sultan MT, Arshad MS, Waheed M, Shariati MA, et al. Biochemistry, Safety, Pharmacological Activities, and Clinical Applications of Turmeric: A Mechanistic Review. Evid Based Complement Alternat Med (2020) 2020:7656919. doi: 10.1155/2020/7656919
19. Gupta SC, Patchva S, Aggarwal BB. Therapeutic Roles of Curcumin: Lessons Learned From Clinical Trials. AAPS J (2013) 15(1):195–218. doi: 10.1208/s12248-012-9432-8
20. Abd El-Hack ME, El-Saadony MT, Swelum AA, Arif M, Abo Ghanima MM, Shukry M, et al. Curcumin, the Active Substance of Turmeric: Its Effects on Health and Ways to Improve its Bioavailability. J Sci Food Agric (2021) 101(4):5747–62. doi: 10.1002/jsfa.11372
21. Razavi BM, Ghasemzadeh-Rahbarard M, Hosseinzadeh H. A Review of Therapeutic Potentials of Turmeric (Curcuma Longa) and Its Active Constituent, Curcumin, on Inflammatory Disorders, Pain, and Their Related Patents. Phytother Res (2021) 35(12):6489–513. doi: 10.1002/ptr.7224

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS
LZ, TY, KY, HC are responsible for the study concept and design. LZ, TY, KY, KY, GL, WX, and HC are responsible for the data collection, data analysis and interpretation; LZ and KY drafted the paper; HC supervised the study; all authors participated in the analysis and interpretation of data and approved the final paper.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.896476/full#supplementary-material
22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ (2021) 372:t1715. doi: 10.1136/bmj.n71

23. Deeks JJ, Higgins JP, Altman DG. Chapter 8: Assessing Risk of Bias in Included Studies. In: Higgins and S Green, editors. Cochrane Handbook or Systematic Reviews of Interventions Version 6.1.0. UK: The Cochrane Collaboration (2020).

24. Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analyzing Data and Undertaking Meta-Analyses. In: Higgins and S Green, editors. Cochrane Handbook or Systematic Reviews of Interventions: UK: The Cochrane Collaboration (2020).

25. Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral Curcumin in the Treatment of Moderate to Severe Psoriasis Vulgaris: A Prospective Clinical Trial. J Am Acad Dermatol (2008) 58 (4):625–31. doi: 10.1016/j.jaad.2007.12.035

26. Cai M, Liu X. Clinical Study on Curcumin Combined With Hyaluronic Acid-Modified Ehanolol in the Treatment of Anti-Plaque Psoriasis. China J Integrat Traditional Chin Western Med Dermatol (2020) 19(4):322–325+ 329. doi: CNKLNSUN:ZXYD.2020-04-008

27. Zhang Y, Liu Z, Ren S, Zeng L. Clinical Observation of Curcumin in the Treatment of Psoriasis Vulgaris: A Prospective Clinical Trial. J Am Acad Dermatol (2008) 58 (4):625–31. doi: 10.1016/j.jaad.2007.12.035

28. Carrión-Gutiérrez M, Ramírez-Bosca A, Navarro-Lopez V, Martínez-Andres A, Asín-Llorca M, Bernd A, et al. Effects of Curcuma Extract and Visible Light on Adults With Plaque Psoriasis. Eur J Dermatol (2015) 25 (3):240–60. doi: 10.1684/ejd.2015.2584

29. Zhu L, Zhu D. Clinical Observation of Curcumin Combined With Hyaluronic Acid-Modified Ehanolol in the Treatment of Anti-Plaque Psoriasis. China J Integrat Traditional Chin Western Med Dermatol (2020) 19(4):322–325+ 329. doi: CNKLNSUN:ZXYD.2020-04-008

30. Yaghoubi H, Babaloo Z, Ayramloo H, et al. Nanocurcumin Restores Aberrant miRNA Expression Pro

31. Zeng L, et al. Changes in Th17 Cells Function After Nanocurcumin Use to Treat Reactive Airways Disease Activity (SLEDAI), IL-6, and TGF-

32. Petracca M, Quaratelli M, Moccia M, Vacca G, Satelliti B, D’Ambrosio G, et al. Prospective Study to Evaluate Efficacy, Safety and Tolerability of Dietary supplenmeNT of Curcumin (BCM95) in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a 44 Mcg TIW (CONTAIN): A Randomized, Controlled Trial. MultSclerRelatDisord (2021) 9:103,274. doi: 10.1016/j.msard.2021.103274

33. Ahmadi M, Hajialiloo M, Dolati S, Eghbali-Fard S, Heydariou H, Gheibi M, et al. The Effects of Nanocurcumin on Treating Cell Apoptosis and Ankylosing Spondylitis Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Biochem (2012) 146(10):118–122. doi: 10.1007/s12090-012-0119-8

34. Shao N, Jia H, Li Y, Li J. Curcumin Improves Treatment Outcome of Takayasu Arteritis Patients by Reducing TNF-α: A Randomized Placebo-Controlled Double-Blind Clinical Trial. ImmunoRes (2017) 65(4):969–74. doi: 10.1107/s12026-017-8917-z

35. Antiga E, Bonciolini V, Volpi W, Del Bianco E, Caproni M. Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients With Psoriasis Vulgaris. BioMed Res Int (2015) 2015:283634. doi: 10.1155/2015/283634

36. Bilia AR, Bergonzi MC, Isacci B, Antiga E, Caproni M. Curcumin Nanoparticles Potentiate Therapeutic Effectiveness of Acitretin in Moderate-to-Severe Psoriasis Patients and Control Serum Cholesterol Levels. J Pharm Pharmacol (2018) 70(7):919–28. doi: 10.1111/jphp.12910

37. Khajehdehi P, Zanjaninejad B, Afkali E, Nazarinia M, Azad F, Malekmakan L, et al. Oral Supplementation of Turmeric Decreases Proteinuria, Hematuria, and Systolic Blood Pressure in Patients Suffering From Relapsing or Refractory Lupus Nephritis: A Randomized and Placebo-Controlled Study. J Ren Nutr (2012) 22(1):50–7. doi: 10.1053/j.jrn.2011.03.002

38. Singhgh Wahono C, Diah Setyowati C, Kaliem H, Nursyah N, Handono K. Effect of Curcuma Xanthorrhiza Supplementation on Systemic Lupus Erythematosus Patients With Hypovitamin D Which Were Given Vitamin D3 Towards Disease Activity (SLEDAI), IL-6, and TGF-β1 Serum. Int J Rheumatol (2017) 2017:678053. doi: 10.1155/2017/678053

39. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Clin Gastroenterol Hepatol (2018) 16(4):548–58. doi: 10.1016/j.cgh.2017.09.002

40. Amalraj A, Varma K, Jacob J, Divya C, Kunnimuthu AR, Stohs SJ, et al. A Novel High Bioavailable Curcumin Formulation Improves Symptoms and DiagnostiC Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study. J Med Food (2017) 20(10):1022–30. doi: 10.1089/jmf.2017.3930

41. Jacob J, Amalraj A, Raj KJJ, Divya C, Kunnimuthu AR, Gopi S. A Novel Bioavailable Hydrogenated Curcuminoids Formulation (CuroWhite™) Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients - A Randomized, Double Blind and Placebo Controlled Study. J Tradit Complement Med (2018) 9(4):346–52. doi: 10.1016/j.ftcm.2018.06.001

42. Chandran B, Goel A. A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients With Active Rheumatoid Arthritis. Phytother Res (2012) 26(11):1719–25. doi: 10.1002/ptr.4639

43. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ (2021) 372:t1715. doi: 10.1136/bmj.n71
Zeng et al. Curcumin for Autoimmune Diseases

55. Sadeghi N, Mansoori A, Shayesteh A, Hashemi SJ. The Effect of Curcumin Supplementation on Clinical Outcomes and Inflammatory Markers in Patients With Ulcerative Colitis. *Phytother Res* (2020) 34(5):1123–33. doi: 10.1002/ptr.6581

56. Banerjee R, Pal P, Penmetsa A, Kathi P, Girish G, Goren I, et al. Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-To-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-Controlled Pilot Study. *J Clin Gastroenterol* (2021) 55(8):702–8. doi: 10.1097/MCG.0000000000001416

57. Wang He, Lei T. Curative Effect Observation of Turmeric Water Decoction Enema Combined With Infliximab in the Treatment of Refractory Ulcerative Colitis. *Clin J Integr Med Digest Med* (2019) 27(03):219–23. doi: CNKI:SUN:ZXWPX.0.2019-03-013

58. Wang Z, Wang L, Zheng Y. Effects of Curcumin on the Proliferation, Apoptosis and KLF6/p21 Protein Expression of HaCaT Cells. *Zhejiang J Integr Med* (2019) 29(05):357–360/436.

59. Bommelager G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, et al. Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn’s Disease After Surgery in a Randomized Controlled Trial. *Clin Gastroenterol Hepatol* (2020) 18(7):1533–1560. doi: 10.1016/j.cgh.2019.08.041

60. Sugimoto K, Ikeya K, Bamba S, Andoh A, Yamasaki H, Mitsuyama K, et al. Novel Anti-Inflammatory Effects of Curcumin in Ulcerative Colitis. *Ann Rheum Dis* (2021) 80(1):14–25. doi: 10.1136/annrheumdis-2020-218272

61. Lee DSW, Rojas OL, Gommerman JL. B Cell Depletion Therapies in Autoimmune Disease: Advances and Mechanistic Insights. *Nat Rev Drug Discovery* (2021) 20(3):179–99. doi: 10.1038/s41573-020-00092-2

62. Karagianni P, Tzioufas AG. Epigenetic Perspectives on Systemic Autoimmune Disease. *Autoimmun Rev* (2019) 104:102315. doi: 10.1016/j.autrev.2019.102315

63. Devarajan P, Chen Z. Autoimmune Effector Memory T Cells: The Bad and the Good. *Immunol Res* (2013) 57(1–3):12–22. doi: 10.1007/s12026-013-8484-1

64. Lin X, Lu L. Cell-Mediated Autoimmune Diseases. *Adv Exp Med Biol* (2020) 1254:145–60. doi: 10.1007/978-981-15-3532-1_11

65. Liu Y, Wang X, Yang F, Zheng Y, Ye T, Yang L. Immunomodulatory Role and Therapeutic Potential of Non-Coding RNAs Mediated by Dendritic Cells in Autoimmune and Immune Tolerance-Related Diseases. *Front Immunol* (2021) 12:678918. doi: 10.3389/fimmu.2021.678918

66. Herrada AA, Escobedo N, Iruretagoyena M, Valenzuela RA, Burgos PI, Cordero LG, et al. In innate Immune Cells’ Contribution to Systemic Lupus Erythematosus. *Front Immunol* (2019) 10:772. doi: 10.3389/fimmu.2019.00772

67. Katsiari CG, Liossis SN, Sfikakis PP. The Pathophysiological Role of Monocytes and Macrophages in Systemic Lupus Erythematosus: A Reappraisal. *Semin Arthritis Rheumatol* (2019) 39(6):491–503. doi: 10.1016/j.semarthrit.2008.11.002

68. Iwata Y, Boström EA, Menke J, Rabalac WA, Morel L, Wada T, et al. Aberrant Macrophages Mediate Defective Kidney Repair That Triggers Nephritis in Lupus-Susceptible Mice. *J Immunol* (2012) 189(9):4568–80. doi: 10.4049/jimmunol.1102154

69. Ding D, Mehta H, McCune WJ, Kaplan MJ. aberrant Phenotype and Function of Myeloid Dendritic Cells in Systemic Lupus Erythematosus. *J Immunol* (2006) 177(9):5878–89. doi: 10.4049/jimmunol.177.9.5878

70. Charles N, Hardwick D, Daugas E, Ileí GG, Rivera J. Basophils and the T Helper 2 Environment can Promote the Development of Lupus Nephritis. *Nat Med* (2010) 16(6):701–7. doi: 10.1038/nm.2159

71. Gupta S, Kaplan MJ. The Role of Neutrophils and Nfεb in Autoimmune and Renal Diseases. *Nat Rev Nephrol* (2016) 12(7):402–13. doi: 10.1038/nrneph.2016.71

72. Sokos GC, Lo MS, Costa Reis P, Sullivan KE. New Insights Into the Immunopathogenesis of Systemic Lupus Erythematosus. *Nat Rev Rheumatol* (2016) 12(12):716–30. doi: 10.1038/nrrheum.2016.186

73. Botto M, Walport MJ, C1q, Autoimmunity and Apoptosis. *Immunobiology* (2002) 205(4–5):395–406. doi: 10.1007/978-0-306-0141

74. Oke V, Gunnarsson I, Dorschner J, Eketjäll S, Zickert A, Niewold TB, et al. High Levels of Circulating Interferons Type I, Type II and Type III Associate With Distinct Clinical Features of Active Systemic Lupus Erythematosus. *Arthritis Res Ther* (2019) 21(1):107. doi: 10.1186/s13075-019-1878-y

75. Nicholls AJ, Wen SW, Hall P, Hickey MJ, Wong CHY. Activation of the Sympathetic Nervous System Modulates Neutrophil Function. *J Leukoc Biol* (2018) 103(2):295–309. doi: 10.1002/jlb.3MA0517-194RR

76. Wing JB, Tanaka A, Sakaguchi S. Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. *Immunity* (2019) 50(2):302–16. doi: 10.1016/j.immuni.2019.01.020

77. Worbs T, Hammerschmidt SI, Förster R. Dendritic Cell Migration in Health and Disease. *Nat Rev Immunol* (2017) 17(1):30–48. doi: 10.1038/ nri.2016.116

78. Patel DD, Kuchroo VK. Th17 Cell Pathway in Human Immunity: Lessons From Genetics and Therapeutic Interventions. *Immunity* (2015) 43 (6):1040–51. doi: 10.1016/j.immuni.2015.12.003

79. Mollazadeh H, Cicero AGF, Blesso CN, Piro M, Majeed M, Sahbehkar A. Immune Modulation by Curcumin: The Role of Interleukin-10. *Crit Rev Food Sci Nutr* (2019) 59(1):89–101. doi: 10.1080/10408398.2017.1358139
93. Montzafi-Borojeni AA, Hattcheshime SM, Esmaeili SA, Johnston TP, Abdollahi E, Sahebkar A. Curcumin: A Natural Modulator of Immune Cells in Systemic Lupus Erythematosus. Autoimmun Rev (2018) 17(2):125–35. doi: 10.1016/j.autrev.2017.11.016

94. Tomoeh MA, Hadianamrei R, Zhao X. A Review of Curcumin and Its Derivatives as Anticancer Agents. Int J Mol Sci (2019) 20(5):1033. doi: 10.3390/ijms20051033

95. Panaro MA, Corrado A, Benameur T, Paolo CF, Cici D, Porro C. The Emerging Role of Curcumin in the Modulation of TLR-4 Signaling Pathway: Focus on Neuroprotective and Anti-Rheumatic Properties. Int J Mol Sci (2020) 21(7):2239. doi: 10.3390/ijms21072239

96. Gonzales AM, Orlando RA. Curcumin and Resveratrol Inhibit Nuclear factor-kappaB-Mediated Cytophene Expression in Acrosph. Nutr Metab (Lond) (2008) 5:17. doi: 10.1186/1743-7075-5-17

97. Han S-S, Keun Y-S, Seo H-J, Surh Y-J. Curcumin Suppresses Activation of NF-κB and AP-1 Induced by Phorbol Ester in Cultured Human Promyelocytic Leukemia Cells. BMB Rep (2002) 35(3):337–342. doi: 10.5483/BMBRep.2002.35.3.337

98. Jiang CX, Wu L, Wu J, Yu ZM, Li XK. Curcumin Analog Exhibited Anti-Inflammatory Activity Through Inhibiting ERK/INK and NF-κB Signaling Pathway. Chin Traditional Herbal Drugs (2016) 47(16):2871–2876. doi: 10.7051/jnmt.2016.16.016

99. Kim GY, Kim KH, Lee SH, Yoon MS, Lee HJ, Moon DO, et al. Curcumin Inhibits Immunostimulatory Function of Dendritic Cells. MAPKs and Translocation of NF-Kappa B as Potential Targets. J Immunol (2005) 174(12):8116–8124. doi: 10.4049/jimmunol.174.12.8116

100. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, et al. Amelioration of Experimental Autoimmune Encephalomyelitis by Curcumin Treatment Through Inhibition of IL-17 Production. Int Immunopharmacol (2009) 9(5):575–581. doi: 10.1016/j.intimp.2009.01.025

101. Handoono K, Pratama MZ, Endharti AT, Kalim H. Treatment of Low Doses Curcumin Could Mediate Th17/Treg Balance Specifically on CD4+ T Cell Cultures of Systemic Lupus Erythematosus Patients. Cent Eur J Immunol (2015) 40(4):461–9. doi: 10.5114/cej.2015.56970

102. Kang D, Li B, Luo L, Jiang W, Lu Q, Rong M, et al. Curcumin Shows Excellent Therapeutic Effect on Psoriasis in Mouse Model. Biochimie (2016) 123(73–80). doi: 10.1016/j.bjochi.2016.01.013

103. Xie L, Li XK, Fumitsui-Fujii N, Kimura H, Matsumoto Y, Isaka Y, et al. Amelioration of Experimental Autoimmune Encephalomyelitis by Curcumin Treatment Through Inhibition of IL-17 Production. Int Immunopharmacol (2009) 9(5):575–581. doi: 10.1016/j.intimp.2009.01.025

104. Liu JQ, Yan YQ, Liu JT, Wang YR, Wang X. Curcumin Prevents Experimental Autoimmune Encephalomyelitis by Inhibiting Proliferation and Efferer CD4+ T Cell Activation. Eur Rev Med Pharmaco. (2019) 23(20):9108–16. doi: 10.26355/eurrev_201910_19314

105. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JWN. Psoriasis. Lancet (2011) 379(9812):1301–15. doi: 10.1016/S0140-6736(20)62549-6

106. Kim WB, Jerome D, Yeung J. Diagnosis and Management of Psoriasis. Fam Fam Physician (2017) 63(4):278–85.

107. Griffiths CE, Barker JN. Pathogenesis and Clinical Features of Psoriasis. Lancet (2007) 370(9588):263–71. doi: 10.1016/S0140-6736(07)61128-3

108. Komiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. J Int J Mol Sci (2019) 20(18):4347. doi: 10.3390/jims20184347

109. Boehmke WH, Schon MP. Psoriasis. Lancet (2015) 386(9997):983–94. doi: 10.1016/S0140-6736(14)61909-7

110. Fitzgerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic Arthritis. Nat Rev Dis Primers (2020) 7(1):15. doi: 10.1038/s41572-020-0029-3

111. Ryan GE, Harris JE, Richmond JM. Resident Memory T Cells in Autoimmune Skin Diseases. Front Immunol (2021) 12:652191. doi: 10.3389/fimmu.2021.652191

112. Greb JE, Goldmim AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. N Engl J Med (2016) 375(12):1608. doi: 10.1056/nejmp16.826

113. Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized Pustular Psoriasis: A Review and Update on Treatment. J Eur Acad Dermatol Venereol. (2018) 32(10):1645–51. doi: 10.1111/jdv.14949

114. Reid C, Griffiths CEM. Psoriasis and Treatment: Past, Present and Future Aspects. Acta DermVenereal. (2020) 100(3):adv00032. doi: 10.2340/00015555-3386

115. Barygina V, Becatti M, Soldi G, Pugnano F, Lotti N, et al. Altered Blood Pressure in the Skin of Psoriatic Patients:Involvement of NADPH Oxidase and Role of Anti-TNF-therapy. Redox Rep (2013) 18(3):180–6. doi: 10.1016/j.jrheum.2009.06.006

116. Skudrzyk A, Aggarwal BB. Curcumin Is a Non - Competitive and Selective Inhibitor of Phospholipase Kinase. FEBS Lett (1994) 342(1):197–200. doi: 10.1006/fsl.1994.1035

117. Varma SR, Sivaprakasam TO, Mishra A. Imiquimod-Induced Psoriasis-Like Inflammation in Differentiated Human Keratinocytes:Its Evaluation Using Curcumin. J Cell Mol Med (2013) 17(3):364–71. doi: 10.1111/j.1476-5383.2011.01634.x
Curcumin for Autoimmune Diseases

177. Hynn S, Eisenstein S. Inflammation and Bowel Disease. Gut (2019) 78:943–50. doi: 10.1136/gutjnl-2018-317928

178. Kelsen JR, Russo P, Sullivan KE. Early-Phase Inflammation and Bowel Disease. Inflammation (2018) 41(6):669–76. doi: 10.1007/s10753-018-04674-9

179. Xavier RJ, Podolsky DK. Inflammation and Autoimmune Disease. J Autoimmun (2007) 31(02):378–85. doi: 10.1016/j.jaut.2006.07.008

180. Alrashdan MS, Cirillo N, McCullough M. Oral Lichen Planus: A Literature Review and Update. Oral Dis (2018) 24(2):163–79. doi: 10.1111/old.12636

181. Lee HS, Lobbestael E, Vermeire S, Sabino J, Cleynen I. Inflammatory Bowel Disease. Front Immunol (2019) 10:276. doi: 10.3389/fimmu.2019.00276

182. Lee HS, Lobbestael E, Vermeire S, Sabino J, Cleynen I. Inflammatory Bowel Disease. Front Immunol (2019) 10:276. doi: 10.3389/fimmu.2019.00276

183. Zenewicz LA, Antov A, Flavell RA. CD4 T-Cell Differentiation and Autoimmunity. J Immunol (2007) 178:3266–73. doi: 10.4049/jimmunol.178.6.3266

184. Li CP, Li JH, He SY, Chen O, Shi L. Effect of Curcumin on P38mapk Signaling Pathway in Rat Primary Articular Chondrocytes. Cell Bio Int (2021) 45(5):976–88. doi: 10.1002/cbin.11541

185. Topcu-Tarladacalisir Y, Akpolat M, Uz YH, Kizilay G, Sapmaz-Metin M, et al. Curcumin Ameliorates IL-1β-Induced Apoptosis in Primary Human Macrophages. Int J Mol Med. (2016) 37(2):435–42. doi: 10.3892/ijmm.2015.2776

186. Liu L, Liu YL, Liu GX, Chen X, Yang K, Yang YX, et al. Curcumin Ameliorates Dextran Sulfate Sodium-Induced Experimental Colitis by Inhibiting the NF-kB Signaling Pathway. Cell Biol Int (2016) 40(4):352–61. doi: 10.1002/cbi.201502504

187. Yang X, Wang Z, Li J, Wang X, Zhang Z, Zhu J. Effects of Curcumin on the Expression of MMP-2 and MMP-9 in the Spinal Cord of EAE Rats. Asian Pac J Cancer Prev (2013) 14(2):3450–8. doi: 10.3322/ncm3.2012-23249

188. Littlejohn EA, Monrad SU. Early Diagnosis and Treatment of Rheumatoid Arthritis. Curr Rheumatol Rep (2013) 15(2):318–25. doi: 10.1007/s11907-013-0358-2

189. Burmester GR, Pope JE. Novel Treatment Strategies in Rheumatoid Arthritis. Curr Opin Rheumatol (2007) 19(2):126–34. doi: 10.1097/01.bor.0000261818.98.0002

190. Enomoto A, Sato E, Yasuda T. Intraepithelial CD8+ Lymphocytes as a Predictive Diagnostic Biomarker for the Remission of Oral Lichen Planus. Hum Pathol (2018) 74:43–53. doi: 10.1016/j.humpath.2017.12.008

191. Shang W. The Effect of Curcumin on PBMC Osteoclastogenesis in Patients With Rheumatoid Arthritis. Clin Exp Rheumatol (2018) 36(5):976–82. doi: 10.1016/j.cler.2018.03.018

192. Ramzan P, Kunnunakkara AB, Newman RA, Aggarwal BB. Bioavailability of Curcumin: Problems and Promises. Mol Pharm (2007) 4(6):807–18. doi: 10.1021/mp700113r

193. Wasserman A. Rheumatoid Arthritis: Common Questions About Diagnosis and Management. Am Fam Physician (2018) 97(7):455–62. doi: 10.4065/mj.2018.02.10

194. Chemin K, Gerstner C, Malmström V. Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis. Front Immunol (2019) 10:276. doi: 10.3389/fimmu.2019.00276

195. Cerkezkayabekir A, et al. Effects of Curcumin on Apoptosis and Oxidative Stress in RA. J Disord Investig (2016) 1:103. doi: 10.5455/jdi.2016.03.01

196. Agha-Hosseini F, Mirzaiz-Digha I, Farmanbar N, Abdollahi M. Oxidative Stress and DNA Damage in Saliva of Human Subjects With Oral Lichen Planus and Oral Squamous Cell Carcinoma. J Oral Pathol Med (2012) 41(10):73–40. doi: 10.1111/j.1600-0714.2012.01172.x

197. Abdolsamadi H, Rafeian N, Oddazari MT. Levels of Salivary Antioxidant Vitamins and Lipid Peroxidation in Patients With Oral Lichen Planus and Healthy Individuals. Chonnam Med J (2014) 50:58–62. doi: 10.4068/cmj.2014.50.2.58

198. Ismail SB, Kumar SK, Zain RB. Oral Lichen Planus and Lichenoid Reactions: Etiopathogenesis, Diagnosis, Management and Malignant Transformation. J Oral Sci (2007) 49(2):89–106. doi: 10.2334/josd.g9.89

199. Raman P, Pitty R, Krithika CL, Anand SPN, Subramani GP. Topical Curcumin: Problems and Promises. Mol Pharm (2007) 4(6):807–18. doi: 10.1021/mp700113r

200. Raman P, Pitty R, Krithika CL, Anand SPN, Subramani GP. Topical Curcumin: Problems and Promises. Mol Pharm (2007) 4(6):807–18. doi: 10.1021/mp700113r

201. Alrashdan MS, Cirillo N, McCullough M. Oral Lichen Planus: A Literature Review and Update. Arch Dermatol Res (2018) 308(8):539–51. doi: 10.1007/s00434-016-1667-2

202. Ryan K, Hegarty AM, Hodgson T. Aetiology, Diagnosis and Treatment of Oral Lichen Planus. Brit J Hosp Med (2014) 75:492–6. doi: 10.12968/hmed.2014.75.9.58

203. Nosratzehi T. Oral Lichen Planus: An Overview of Potential Risk Factors, Biomarkers and Treatments. Asian Pac J Cancer Prev (2018) 19(5):1161–7. doi: 10.22034/APJCP.2018.19.5.1161

204. Agha-Hosseini F, Mirzaiz-Digha I, Farmanbar N, Abdollahi M. Oxidative Stress and DNA Damage in Saliva of Human Subjects With Oral Lichen Planus and Oral Squamous Cell Carcinoma. J Oral Pathol Med (2012) 41(10):73–40. doi: 10.1111/j.1600-0714.2012.01172.x

205. Nosratzehi T. Oral Lichen Planus: An Overview of Potential Risk Factors, Biomarkers and Treatments. Asian Pac J Cancer Prev (2018) 19(5):1161–7. doi: 10.22034/APJCP.2018.19.5.1161

206. Agha-Hosseini F, Mirzaiz-Digha I, Farmanbar N, Abdollahi M. Oxidative Stress and DNA Damage in Saliva of Human Subjects With Oral Lichen Planus and Oral Squamous Cell Carcinoma. J Oral Pathol Med (2012) 41(10):73–40. doi: 10.1111/j.1600-0714.2012.01172.x

207. Abdolsamadi H, Rafeian N, Oddazari MT. Levels of Salivary Antioxidant Vitamins and Lipid Peroxidation in Patients With Oral Lichen Planus and Healthy Individuals. Chonnam Med J (2014) 50:58–62. doi: 10.4068/cmj.2014.50.2.58

208. Ismail SB, Kumar SK, Zain RB. Oral Lichen Planus and Lichenoid Reactions: Etiopathogenesis, Diagnosis, Management and Malignant Transformation. J Oral Sci (2007) 49(2):89–106. doi: 10.2334/josd.g9.89

209. Anand P, Kunnunakkara AB, Newman RA, Aggarwal BB. Bioavailability of Curcumin: Problems and Promises. Mol Pharm (2007) 4(6):807–18. doi: 10.1021/mp700113r

210. Cheng AL, Hus CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I Clinical Trial of Curcumin, a Chemopreventive Agent, In Patients With High-Risk or Pre-Malignant Lesions. Anticancer Res (2001) 21(4B):2895–900.